Search Results
Your search for ASCO matches 21361 pages
Showing 20351 - 20400Measuring Minimal Residual Disease Levels Proves to Be a Powerful Tool for Guiding Leukemia Treatment
According to a prospective study led by researchers at St. Jude Children's Research Hospital, measuring the concentration of leukemia cells in patient bone marrow during the first 46 days of chemotherapy may help boost survival of young leukemia patients by better matching patients with the right...
Preliminary Study Reveals Gene Regulatory Path as Target for Aggressive Pediatric Brain Cancer
Working with cells taken from children with a very rare but aggressive form of brain cancer, Johns Hopkins Kimmel Cancer Center scientists have identified a genetic pathway that acts as a master regulator of thousands of genes, and may spur cancer cell growth and resistance to anticancer treatment. ...
Study Finds U.S. Spends More on Cancer Care but Saves Fewer Lives Than Western Europe
Despite sharp increases in spending on cancer treatment, cancer mortality rates in the United States have decreased only modestly since 1970. Researchers led by Samir Soneji, PhD, of Dartmouth's Norris Cotton Cancer Center and The Dartmouth Institute for Health Policy & Clinical Practice...
New Breast Cancer Test Links Immune ‘Hotspots’ to Better Survival
Scientists have developed a new test that predicts the survival chances of women with breast cancer by analyzing images of “hotspots” where there has been a fierce immune reaction to a tumor. Using statistical software previously used in criminology studies of crime hotspots,...
Breast Cancer Risk May Increase in Women Who Have First-Degree Relatives With a History of Prostate Cancer
Having a family history of prostate cancer among first-degree relatives may increase a woman's risk of developing breast cancer. Researchers from multiple institutions published their findings in a study by Beebe-Dimmer et al in Cancer. The study's results indicate that clinicians should take a...
International Lymphoma Radiation Oncology Group Issues Treatment Guidelines for Pediatric Hodgkin Lymphoma
The International Lymphoma Radiation Oncology Group (ILROG) has issued a guideline outlining the use of three-dimensional (3D) computed tomography (CT)–based radiation therapy planning and volumetric image guidance, specifically to more effectively treat pediatric Hodgkin lymphoma. The...
Chromosomal Rearrangement May Be the Key to Progress Against Aggressive Infant Leukemia
The St. Jude Children's Research Hospital–Washington University Pediatric Cancer Genome Project reports that a highly aggressive form of leukemia in infants has surprisingly few mutations beyond the chromosomal rearrangement that affects the MLL gene. The findings, reported by Andersson et al ...
Annual ASCO Report Shows Widespread Disturbance in Oncology Practice, Amid Growing Patient Demand and Administrative Burden
The U.S. cancer care system faces tremendous turbulence while dealing with growing numbers of cancer patients and survivors, mounting pressures to control rising health-care costs, and widespread oncology practice transformation, reports a new study by the American Society of Clinical Oncology...
NCCN Publishes New Guidelines for Smoking Cessation
Tobacco-related diseases are the most preventable cause of death worldwide; smoking cessation leads to improvement in cancer treatment outcomes, as well as decreased tumor recurrence. According to the American Cancer Society, in 2015, nearly 171,000 of the estimated 589,430 cancer deaths in the...
Concurrent Chemoradiation Therapy at High-Volume Facilities Improves Survival for NSCLC
Patients treated with definitive concurrent chemotherapy and radiation therapy for stage III non–small cell lung cancer (NSCLC) have longer overall survival when treated by highly experienced facilities, whether or not they are academic or community cancer centers. Researchers from the Yale...
Study Finds Lycopene May Be Associated With Lower Risk for Kidney Cancer in Postmenopausal Women
A higher intake by postmenopausal women of lycopene, an antioxidant found in foods like tomatoes, watermelon, and papaya, may lower the risk of renal cell carcinoma, a type of kidney cancer. A study describing these findings was published by Ho et al in Cancer. In 2014, 63,920 estimated new cases...
Clinical Trial Suggests Temozolomide-Based Chemoradiation Is Best for Low-Grade Brain Tumors
New clinical trial findings provide further evidence that combining chemotherapy with radiation therapy is the best treatment for people with a low-grade form of brain cancer. The findings come from a phase II study co-led by a researcher at Ohio State University Comprehensive Cancer...
Researchers Map Genomic Landscape of Childhood Adrenocortical Tumors for the First Time
In an advance that could lead to better identification of malignant pediatric adrenocortical tumors, and ultimately to better treatment, researchers have mapped the genomic landscape of these rare childhood tumors. Their genomic mapping has revealed unprecedented details, not only of the aberrant...
New Analysis Reports Increased Risk of Thyroid Cancer After Breast Cancer Diagnosis
Breast cancer survivors are at increased risk of developing thyroid cancer, especially within 5 years of their breast cancer diagnosis, according to a new analysis of a large national database. The study results were presented at the Endocrine Society's 97th Annual Meeting. “Recognition of...
Study Shows Targeting Cancer Cell ‘Cloak’ Could Benefit Drug Delivery
Cancer cells can cloak themselves within tumors by hiding behind a dense layer of cellular stroma. According to a new study by the Translational Genomics Research Institute (TGen), drugs that target and strip away the stroma would pave the way for other drugs to reach the cancerous cells within the ...
AACR Names Nancy E. Davidson, MD, President-Elect for 2015-2016
The American Association for Cancer Research (AACR) today announced the election of Nancy E. Davidson, MD, Director of the University of Pittsburgh Cancer Institute and UPMC CancerCenter in Pittsburgh, as its President-Elect for 2015–2016. Dr. Davidson will officially become President-Elect...
FDA Approves Dinutuximab Combination for Pediatric Patients With High-Risk Neuroblastoma
The U.S. Food and Drug Administration has approved dinutuximab (Unituxin) as part of first-line therapy for pediatric patients with high-risk neuroblastoma. Dinutuximab, a chimeric monoclonal antibody that binds to the surface of neuroblastoma cells, is being approved for use as part of a...
Neoadjuvant Chemotherapy for Breast Cancer Increases Chances of Lumpectomy, Decreases Chances of Mastectomy
Patients with larger malignant tumors of the breast who undergo chemotherapy before a breast cancer operation are more likely to undergo a lumpectomy than a mastectomy, according to a study published by Killelea et al in the Journal of the American College of Surgeons. Study investigators from...
Inherited Gene Variation Leaves Young Leukemia Patients at Risk for Peripheral Neuropathy
St. Jude Children’s Research Hospital scientists have identified the first genetic variation that is associated with an increased risk and severity of peripheral neuropathy following treatment with a widely used anticancer drug. Investigators also found evidence of how it may be possible to...
New Study Assesses Inclusion of Family in Cancer Patients’ Treatment Decisions
Family members often play an important role in providing care for patients with cancer, but which patients are more or less likely to involve family members in decisions regarding their care is not well known. A new study published by Hobbs et al in Cancer provides some insights and may help...
FDA Approves First Biosimilar Product Filgrastim‑Sndz
The U.S. Food and Drug Administration (FDA) today approved filgrastim-sndz (Zarxio), the first biosimilar product approved in the United States. A biosimilar product is a biologic product that is approved based on a showing that it is highly similar to an already-approved biologic. The biosimilar...
Preclinical Study Shows Promise for the Development of Personalized Cellular Therapy for Brain Cancer
Immune cells engineered to seek out and attack a type of deadly brain cancer were found to be safe and effective at controlling tumor growth in mice that were treated with these modified cells, according a team from the Perelman School of Medicine at the University of Pennsylvania and the Novartis...
Harold Varmus, MD, Stepping Down as Director of the National Cancer Institute
Harold Varmus, MD, who has led the National Cancer Institute (NCI) at the National Institutes of Health (NIH) for nearly 5 years, has announced that he will step down from his post, effective March 31, 2015. Dr. Varmus will be joining Weill Cornell Medical College's faculty as the Lewis Thomas...
Study Finds Websites That Market Personalized Cancer Care Services Overemphasize Benefits
A recent analysis of 55 Internet websites marketing a broad range of tests and services that promise the ability to personalize cancer treatment has found that the websites often overemphasize their purported benefits and downplay their limitations. In addition, the study results show that the...
FDA Approves Nivolumab to Treat Metastatic Squamous Non–Small Cell Lung Cancer
The U.S. Food and Drug Administration (FDA) today approved the PD-1 inhibitor nivolumab (Opdivo) for the treatment of patients with metastatic squamous non–small cell lung cancer (NSCLC) who have progressed on or after platinum-based chemotherapy. Nivolumab is a monoclonal antibody that binds ...
Early Study Shows Cabazitaxel May Be More Effective Than Docetaxel in Some Patients With Advanced Prostate Cancer
In a new study reported by de Leeuw et al in Clinical Cancer Research, researchers found that the novel taxane cabazitaxel (Jevtana) has properties that could make it more effective than docetaxel in some patients with advanced prostate cancer. This hypothesis is currently being tested in a phase...
Study Finds Improved Survival for Young Patients With Brain Metastases Who Receive Stereotactic Radiosurgery Alone
Cancer patients with limited brain metastases (one to four tumors) who are 50 years old and younger should receive stereotactic radiosurgery without whole-brain radiotherapy, according to a study by Saghal et al in the International Journal of Radiation Oncology • Biology • Physics....
Human Reovirus Formulation Receives FDA Orphan Drug Designation for Fallopian Tube Cancer
The U.S. Food and Drug Administration (FDA) has granted Orphan Drug designation for Oncolytics Biotech’s proprietary formulation of the human reovirus (Reolysin) for the treatment of fallopian tube cancer. The designation was granted on the basis of the company's December 2014 application for ...
Adjuvant Chemotherapy Improves Survival in Patients With Locally Advanced Bladder Cancer
Patients who received chemotherapy after bladder cancer surgery demonstrated an approximately 30% lower risk of death than those who underwent surgery alone, according to an analysis presented by researchers at the Icahn School of Medicine at Mount Sinai at the 2015 Genitourinary Cancers Symposium, ...
FDA Grants Breakthrough Therapy Designation to EBV-Targeted T Cells for Treatment of EBV-Associated Lymphoproliferative Disease
The U.S. Food and Drug Administration has granted Breakthrough Therapy designation to Memorial Sloan Kettering Cancer Center and Atara Biotherapeutics’ optioned cytotoxic T lymphocytes activated against Epstein-Barr virus (EBV-CTL) in the treatment of patients with rituximab...
Sipuleucel-T Demonstrates Sustained Immune Response 2 Years After Treatment in Biochemically Recurrent Prostate Cancer
Preliminary results from the phase II STAND trial have demonstrated a robust immune response with sipuleucel-T (Provenge) that continues 2 years after completing treatment in men with biochemically recurrent prostate cancer. The findings, along with data from an ongoing phase IV registry related to ...
Study Shows Lack of RNA Editing Leads to Melanoma Growth and Metastasis
In a new study reported by Shoshan et al in Nature Cell Biology, researchers at The University of Texas MD Anderson Cancer Center established a link between melanoma and lack of RNA editing, which leads to tumor growth and progression through manipulation of proteins. Study Findings Study lead...
Active Surveillance of Intermediate-Risk Prostate Cancer Associated With Decreased Survival
An analysis of data on 945 patients with prostate cancer that is managed with active surveillance shows differences in outcomes depending on whether the patient was low or intermediate risk at diagnosis. Compared to patients with low-risk disease, those with intermediate-risk cancer (PSA > 10...
Adjuvant Sorafenib and Sunitinib Do Not Improve Outcomes in Locally Advanced Kidney Cancer
Findings from a federally funded study suggest that patients with locally advanced kidney cancer should not be treated with either adjuvant sorafenib (Nexavar) or sunitinib (Sutent). The average period to disease recurrence was similar between those who received sorafenib or sunitinib after surgery ...
Men Who Have Had Testicular Cancer May Be More Likely to Develop Prostate Cancer
A case-control study of close to 180,000 men suggests that the incidence of prostate cancer is higher among men with a history of testicular cancer (12.6%) than among those without a history of testicular cancer (2.8%). Men who have had testicular cancer were also more likely to develop...
Early Evidence of Increase in Higher-Risk Prostate Cancers From 2011 to 2013
An analysis of data on roughly 87,500 men treated for prostate cancer since 2005 found a notable increase in higher-risk cases of the disease between 2011 and 2013. The retrospective analysis of patient data found the proportion of men diagnosed with intermediate- and high-risk disease increased by ...
Androgen Receptor Abnormality May Not Be Associated With Primary Resistance to Taxane Chemotherapy
Findings from a small prospective study suggest that androgen receptor V7 (or AR-V7) status does not significantly affect response to taxane chemotherapy in men with metastatic castration-resistant prostate cancer. Treatment outcomes were largely similar for the 17 patients with...
FDA Approves Panobinostat Combination for the Treatment of Multiple Myeloma
The U.S. Food and Drug Administration (FDA) today approved panobinostat (Farydak) in combination with bortezomib (Velcade) and dexamethasone for the treatment of patients with multiple myeloma. Panobinostat is the first histone deacetylase (HDAC) inhibitor approved to treat multiple myeloma. It is...
Classic vs Rare EGFR Mutations in Non–Small Cell Lung Cancer Have Distinct Epidemiology, Clinical Implications
Certain rare epidermal growth factor receptor (EGFR) mutations are associated with tobacco smoking, worse prognosis, and poor response to EGFR tyrosine kinase inhibitor therapy, compared with more common, classic EGFR mutations. However, as not all rare mutations are the same, testing and therapy...
Sensor Technology May Help Improve the Accuracy of Clinical Breast Exams
Sensor technology has the potential to significantly improve the teaching of proper technique for clinical breast exams, according to a new study by researchers at the University of Wisconsin School of Medicine and Public Health. The results of the study were published in a correspondence in The...
Study Shows That Previous Cancer ‘False Alarms’ May Discourage Patients From Screening Future Symptoms
Cancer researchers at University College London (UCL) have found that a cancer false alarm could discourage patients from checking out cancer symptoms they develop in the future. More than 80% of patients with potential cancer symptoms are given the all-clear after investigations. But according to ...
FDA Grants Cobimetinib Priority Review for Use in Combination With Vemurafenib in Advanced Melanoma
The U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review for Genentech’s New Drug Application (NDA) for cobimetinib in combination with vemurafenib (Zelboraf) for the treatment of people with BRAF V600 mutation–positive advanced melanoma. The FDA will make a...
FDA Approves Lenalidomide in Combination With Dexamethasone for Newly Diagnosed Multiple Myeloma
The U.S. Food and Drug Administration (FDA) has expanded the existing indication for lenalidomide (Revlimid) in combination with dexamethasone to include patients newly diagnosed with multiple myeloma. Lenalidomide plus dexamethasone was previously approved in June 2006 for use in multiple myeloma...
Survivors of Childhood Cancer at Risk for Developing Hormone Deficiencies as Adults
Decades after undergoing cranial irradiation for childhood cancer, St. Jude Children's Research Hospital investigators found that adult survivors of pediatric cancer remain at risk for pituitary hormone deficiencies, which may diminish their health and quality of life. Chemaitilly et al published...
12-Year Study Suggests Procedures to Prevent Cervical Cancer Do Not Affect Fertility
Common surgical procedures used to diagnose and treat precancerous cervical lesions do not decrease women's chances of becoming pregnant, according to a study conducted by Kaiser Permanente Northwest, which followed nearly 100,000 women for up to 12 years. In fact, researchers found that women ...
ASCO Expresses Concern Over the New CMS Oncology Care Model
On Thursday, February 12, 2015, the U.S. Department of Health and Human Services announced its new Oncology Care Model, a multipayer payment and care delivery model meant to support better health-care coordination for patients with cancer. Although commending the Centers for Medicare & Medicaid ...
FDA Approves Lenvatinib for Progressive Radioiodine-Refractory Differentiated Thyroid Cancer
The U.S. Food and Drug Administration (FDA) today granted approval to lenvatinib (Lenvima) to treat patients with progressive, differentiated thyroid cancer whose disease progressed despite receiving radioactive iodine therapy. Lenvatinib is a tyrosine kinase inhibitor that binds to multiple sites...
Nutrient-Wide Association Study Shows Increased Coffee Intake May Be Associated With Lower Risk of Endometrial Cancer
Women who drank about four cups of coffee per day appeared to have decreased endometrial cancer risk compared with those who drank less than a cup each day, according to a study published by Merritt et al in Cancer Epidemiology, Biomarkers & Prevention. A New Approach “We used a...
Lenvatinib Shows Promise for Patients With Radioiodine-Refractory Thyroid Cancer in Phase III Study
In a phase III study led by researchers at The University of Texas MD Anderson Cancer Center, the oral antiangiogenic therapy lenvatinib has shown dramatic improvement in progression-free survival in patients with advanced radioiodine-refractory thyroid cancer. Their findings are published by...
FDA Grants Orphan Drug Designation to Human Reovirus Formulation for the Treatment of Ovarian Cancer
Oncolytics Biotech, Inc, a clinical-stage biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics, has announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug designation for its proprietary formulation of the human reovirus...
